As part of our mission to eliminate cancer, Torrance Memorial Hunt Cancer Institute physicians conduct several clinical trials to test new treatments for both common and rare cancers. Look through our clinical trials list to find studies for which you may be eligible.

Hunt Cancer Institute Active Clinical Trials

These studies are currently enrolling participants.

Disease Title Summary Status Investigator
Breast Cancer CONTESSA: ODO-TE-B301A. Odonate/inVentive Phase 3 Study of Tesetaxel(PO) plus reduced dose of Capecitabine(PO) vs Capecitabine alone in patients with HR (+), HER2 (-), locally advanced or metastatic breast cancer, previously treated with a taxane. Open/Active Swati Sikaria, MD
Breast Cancer EMERALD: RAD1901-308 ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE (ENDOCRINE THERAPY) FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL. Open/Active David Chan, MD
Colorectal Cancer NOVA:CG001, Clinical Genomics/Beaufort Only one blood collection is required for enrollment. Followed by ONE scan/test (CT/MRI/PET/endoscopy). Must be in remission from Stage II/III CRC and within 6 mos-24 months after treatment, with no evidence of disease, no other current cancer. Blood draw to be done within 6 months prior to scan, or on day of, but not after contrast agents. Open/Active David Chan, MD
GI Cancer PASCAL: CG013, Clinical Genomics/Beaufort Enrolling reoccurrance arm only. Only one blood collection is required within 4 weeks of SCAN. Must be in remission from Stage II/III CRC and within 6 mos-24 months after treatment, with no evidence of disease, no other current cancer. Coincides with NOVA. Open/Active David Chan, MD
Lung Cancer VISION: MS200095-0022 Merck/Quintiles

Pre-screening site only. Phase II 2nd/3rd line – Stage IV NSCLC- all histology included- ALK/EGFR Negative. Must not have received more than two lines of therapy. Seeking archival tissue for MET exon 14 testing***. MET AMP/MET exon 14 testing is available using Guardant 360 blood draw. Either archival tissue and/or Guardant may be used, MD discretion.

***If positive for MET AMP/exon 14 then pt will be referred to City of Hope for treatment arm of trial.

 Open/Active Andrew Horodner, MD
All Solid Tumors LexentBio: LB-1985106 All solid tumors. No lymphoma or heme. Currently enrolling ONLY New Dx/Progression- UNRESECTABLE. Patients will be enrolled before the start of any new therapy (targeted, endocrine, chemotherapy, radiation, etc.) Blood (20mLs-2 tubes) will be collected before the start of any treatment and collected every 3-4 weeks depending on treatment cycle. Subject can stay on study until progression, etc. Open/Active David Chan, MD

Active Trials - UCLA Trials

The following clinical trials are available at Torrance Memorial Physician Network Cancer Care and are in coordination with the TRIO-US / Clinical Trials Network.

Disease Title Summary Status Investigator
Breast Cancer ‐ ADJUVANT (ER +, HER2 neg) TRIO 033 ‐ Novartis CLEE011O12301C "NATALEE" Phase III, multicenter, randomized, open‐label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor‐positive, HER2‐negative, early breast cancer (New Adjuvant Trial with Ribociclib.[LEE011]:NATALEE) Open/Active David Chan, MD
Pancreatic Cancer ARMO AM0010‐301 SEQUOIA A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second‐line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First‐Line Gemcitabine Containing Regimen Open/Active Hugo Hool, MD
Colorectal Cancer Abbvie M14‐064 Phase 2 Study Comparing Efficacy and Safety of ABT‐165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab. Open/Active Thomas Lowe, MD
Lymphoma Incyte INCB 50465‐204 (CITADEL‐204) Open Label 2‐Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor. Open/Active Swati Sikaria, MD
Lung Cancer BMS CA209‐817 NSCLC (CHECKMATE 817) A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Lung Malignancies. Open/Active Thomas Lowe, MD
Other BMS 209‐655 Hodgkin lymphoma molecular profiling and clinical outcomes in U.S Community oncology practice. Open/Active Hugo Hool, MD

Cedars-Sinai Trials

Disease Title Summary Status Investigator
DCIS/Breast Cancer COMET AFT-25 Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial. Open/Active Swati Sikaria, MD
Urology/Renal Cell Carcinoma CANTATA- CX-839-008 A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC). Open/Active Vanessa Dickey, MD
Basket Trial TAPUR- ASCO TESTING THE USE OF FDA APPROVED DRUGS THAT TARGET A SPECIFIC ABNORMALITY IN A TUMOR GENE IN PEOPLE WITH ADVANCED STAGE CANCER. Open/Active Swati Sikaria, MD

For More Information

For more information about the clinical trials at Torrance Memorial, call 310-517-7077.